巴瑞替尼治疗传统合成DMARD难治性类风湿关节炎的III期研究患者报告结局
这项III期研究纳入对传统合成DMARD应答不足或不耐受的活动性类风湿关节炎患者,随机分为安慰剂组、巴瑞替尼2 mg每日一次组和4 mg每日一次组。结果显示,与安慰剂相比,巴瑞替尼2 mg和4 mg在第12周及第24周均显著改善HAQ-DI、患者总体评估、疼痛、晨僵、疲劳及生活质量等多个患者报告结局。
要点
- 巴瑞替尼2 mg和4 mg在第12周及24周均显著改善HAQ-DI、PtGA、疼痛等患者报告结局。
- 巴瑞替尼4 mg在第24周显著改善FACIT-F疲劳评分,2 mg显著改善EuroQoL VAS。
- 患者电子日记记录的晨僵持续时间与严重程度、最严重疲劳及最严重关节痛均显著改善。
核心结论
- 巴瑞替尼2 mg或4 mg在身体功能、晨僵、疲劳、疼痛和生活质量等多个领域较安慰剂显著改善患者报告结局。
研究设计与样本
- III期随机对照研究,患者按1:1:1随机分配至安慰剂组(N=228)、巴瑞替尼2 mg每日一次组(N=229)或巴瑞替尼4 mg每日一次组(N=227)。
- 研究对象为对传统合成DMARD应答不足或不耐受的活动性类风湿关节炎患者。
- 主要时间点为第12周,分类变量采用逻辑回归、连续变量采用协方差分析进行组间比较。
主要发现
- 第12周和第24周时,巴瑞替尼2 mg和4 mg组在HAQ-DI、PtGA、疼痛、每日日记指标、EuroQoL指数评分和SF-36躯体成分评分方面均较安慰剂组有统计学显著改善。
- 第24周时,巴瑞替尼2 mg组EuroQoL VAS和巴瑞替尼4 mg组FACIT-F分别较安慰剂组有统计学显著改善。
临床怎么用
- 对于传统合成DMARD应答不足或不耐受的活动性RA患者,巴瑞替尼2 mg或4 mg每日一次可改善身体功能、晨僵、疲劳、疼痛及生活质量等患者报告结局。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs. METHODS: In this phase III study, patients were randomised 1:1:1 to placebo (N=228), baricitinib 2 mg once daily (QD, N=229) or baricitinib 4 mg QD (N=227). PROs included the Health Assessment Questionnaire-Disability Index (HAQ-DI), Patient's Global Assessment of Disease Activity (PtGA), patient's assessment of pain, measures from patient electronic daily diaries (duration and severity of morning joint stiffness (MJS), Worst Tiredness, Worst Joint Pain), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), SF-36, EuroQol 5-D index scores and visual analogue scales (VAS) and the Work Productivity and Activity Impairment Questionnaire-RA. The primary time point for the study was week 12. Treatment comparisons were assessed with logistic regression for categorical measures and analysis of covariance for continuous variables. RESULTS: Statistically significant improvements were observed for both baricitinib groups versus placebo in HAQ-DI, PtGA, pain, daily diary measures, EuroQoL index scores and SF-36 physical component score at week 12 and for those measures when assessed at week 24. Baricitinib 2 mg and baricitinib 4 mg were statistically significantly improved versus placebo for the EuroQoL VAS and FACIT-F, respectively, at week 24. CONCLUSIONS: Baricitinib 2 or 4 mg provided significant improvement versus placebo in PROs across different domains of RA, including physical function, MJS, fatigue, pain and quality of life. TRIAL REGISTRATION NUMBER: NCT01721057; Results.
引用
- Emery P, Blanco R, Maldonado Cocco J, et al. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open. 2017. PMID: 28405473. doi:10.1136/rmdopen-2016-000410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。